SinoMab Bioscience Ltd. is a clinical stage biopharmaceutical company, which engages in the research, development, and manufacture of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody-based biologics. The company employs 61 full-time employees The company went IPO on 2019-11-12. The firm primarily develops mAb-based biologics and new chemical entities (NCE) and its product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The firm is also developing drugs such as SM17, which has the potential to treat atopic dermatitis (AD), asthma, idiopathic pulmonary fibrosis (IPF) and other immune diseases, and SN1011, which targets systemic lupus erythematosus (SLE), pemphigus, multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD).
03681.HK stock price ended at $1.44 on 星期五, after dropping 6.49%
On the latest trading day Jan 16, 2026, the stock price of 03681.HK fell by 6.49%, dropping from $1.54 to $1.44. During the session, the stock saw a volatility of 6.94%, with prices oscillating between a daily low of $1.44 and a high of $1.54. On the latest trading day, the trading volume for 03681.HK rose by 141.3K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 4.2M shares were traded, with a market value of approximately $1.9B.